|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our results suggest a strategy to relieve a STAT1/3-dependent therapeutic barrier and enhance oHSV-1 oncolytic activity in GBM.<b>Significance:</b> These findings suggest a strategy to enhance the therapeutic efficacy of oncolytic virotherapy in glioblastoma.<i></i>.
|
29118089 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment also elicited (a) suppression of the M2-linked tumor-promoting proteins STAT3, ARG1, and IL10, (b) induction of the M1-linked anti-tumor proteins STAT1 and inducible nitric oxide synthase in the TAM, (c) elimination of CD133(+) GBM stem cells, and (d) activation of caspase3 in the GBM cells.
|
30041669 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
STAT1 is enriched in CSCs in cancer cell lines, patient-derived human breast cancer, and CD95<sup>high</sup>-expressing glioblastoma neurospheres.
|
28273453 |
2017 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma.
|
28671669 |
2017 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction network analysis indicated that the GBM-associated proteins in the RNA processing were linked to crucial signaling transduction modulators including epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 1 (STAT1), and mitogen-activated protein kinase 1 (MAPK1), which were further connected to the proteins important for neuronal structural integrity, development and functions.
|
28341197 |
2017 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we found that enforced miR203 expression in glioblastoma suppressed STAT1 expression directly, as well as that of a number of STAT1 regulated genes.
|
27705947 |
2016 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profile analysis performed on murine xenograft models of glioblastoma showed increased transcriptional levels of STAT1/IRF1 signaling in bevacizumab resistant tumors compared to control tumors.
|
26362401 |
2015 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subsequently, the expression of STAT-1 was analyzed with real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) in glioblastoma and control brain tissues.
|
24878287 |
2014 |
|
Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Unlike in the case of IFN-γ, the restoration of TAP-1 and LMP-2 by down-regulation of IGF-1 in Glioblastoma cells was not correlated to the tyrosine phosphorylation of STAT 1.
|
23526983 |
2013 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study suggest that increased expression of STAT1 by transfection with STAT1 plasmid synergistically inhibits human U87MG glioblastoma cell growth in vitro.
|
23600941 |
2013 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
In our study performed by immunohistochemistry, 22 out of 46 glioblastomas (48%) were strongly positive for staining with a STAT-1 antibody, 9 (20%) showed an intermediate reactivity, 8 (17%) low immunoreactivity, and 7 (15%) were completely negative.
|
18225539 |
2008 |